Dosing of cabozantinib formulations
MA39735AUndetermined Publication Date: 2017-01-25EXELIXIS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA39735
- Authority / Receiving Office
- MA · MA
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-03-17
- Filing Date
- 2015-03-17
- Publication Date
- 2017-01-25
Abstract
The invention relates to administration of various pharmaceutical formulations of n- (4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide, (cabozantinib) a c-met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
Need to check novelty before this filing date? Find Prior Art